Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 5.2 2.36% 0.12
BCRX closed up 2.36 percent on Wednesday, October 18, 2017, on 47 percent of normal volume.

Earnings due: Nov 6

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical BCRX trend table...

Date Alert Name Type % Chg
Oct 18 Bollinger Band Squeeze Range Contraction 0.00%
Oct 18 Lower Bollinger Band Walk Other 0.00%
Oct 17 Narrow Range Bar Range Contraction 2.36%
Oct 17 Bollinger Band Squeeze Range Contraction 2.36%
Oct 17 Lower Bollinger Band Walk Other 2.36%

Older signals for BCRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 9.25
52 Week Low 3.75
Average Volume 1,752,120
200-Day Moving Average 5.9935
50-Day Moving Average 5.0181
20-Day Moving Average 5.2101
10-Day Moving Average 5.167
Average True Range 0.2132
ADX 18.76
+DI 21.55
-DI 17.85
Chandelier Exit (Long, 3 ATRs ) 4.9704
Chandelier Exit (Short, 3 ATRs ) 5.5696
Upper Bollinger Band 5.3431
Lower Bollinger Band 5.0771
Percent B (%b) 0.46
BandWidth 5.105468
MACD Line -0.0077
MACD Signal Line 0.0141
MACD Histogram -0.0218
Fundamentals Value
Market Cap 418.23 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -8.39
Price-to-Sales 14.42
Price-to-Book 17.56
PEG Ratio -0.35
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.41
Resistance 3 (R3) 5.39 5.31 5.38
Resistance 2 (R2) 5.31 5.25 5.32 5.36
Resistance 1 (R1) 5.25 5.22 5.28 5.27 5.35
Pivot Point 5.17 5.17 5.18 5.18 5.17
Support 1 (S1) 5.11 5.11 5.14 5.13 5.05
Support 2 (S2) 5.03 5.08 5.04 5.04
Support 3 (S3) 4.97 5.03 5.03
Support 4 (S4) 4.99